Case study: real-world benefits of an oncology navigation program
A novel cancer treatment may hold much promise—but only if the patient is adherent to therapy. Consider, for example, that up to 24 percent of cancer patients have skipped filling their prescriptions altogether, and up to 29 percent skip their doctor appointments.1
The underlying reasons for non-adherence vary from patient to patient based on a range of unique barriers—from financial challenges and accessibility to side effects, health illiteracy, work and family interruptions, and the influence of mental health issues.
To address these barriers and give cancer drugs the best chance of success, Lash Group sought to determine the impact of a patient-centered support program on multiple myeloma treatment adherence.